相关实验视频

Updated: Jan 10, 2026

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

通过TRAF2 deubiquitination诱导的HSP47抑制诱导的CD155表达促进了瘤免疫逃避

Haochen Mou^1,2,3,4, Hao Qu^1,2,3,4, Shixin Chen^1,2,3,4

¹Department of Orthopaedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, People's Republic of China.

Journal for immunotherapy of cancer

|November 28, 2025

概括

抑制骨髓瘤中热冲击蛋白47 (HSP47) 通过上调CD155.5来增加免疫逃避. 将HSP47抑制与TIGIT阻断相结合显示出癌症治疗的前景.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

热冲击蛋白47 (HSP47) 对于蛋白质质量控制和瘤进展至关重要.
它在癌症免疫力,特别是骨髓瘤 (OS) 中的作用尚不清楚.
这项研究研究了HSP47抑制对通过OS的CD155/TIGIT轴对免疫逃避的影响.

研究的目的:

为了阐明HSP47抑制如何调节骨髓瘤中的免疫逃避.
检查CD155/TIGIT轴在这个过程中的特定作用.
评估涉及HSP47抑制的组合疗法.

主要方法:

利用OS细胞系和小鼠模型来评估HSP47抑制对瘤生长和免疫反应的影响.
分析了免疫检查点分子表达 (CD155,TIGIT) 使用流动细胞计,免疫光和西部涂抹.
在临床前模型中评估了与CD155阻断或NF-κB抑制剂的组合疗法.

主要成果:

抑制HSP47增加了CD155的表达,通过TIGIT损害了CD8+T细胞的抗瘤活性.
在机制上,HSP47抑制减少了TRAF2的无处不在,增强了NF-κB信号和CD155上调.
与抗TIGIT或NF-κB抑制剂联合抑制HSP47,显著抑制了OS进展,并改善了小鼠的生存率.

结论:

通过TRAF2-NF-κB通路对CD155进行上调,从而阻碍CD8+ T细胞免疫力,HSP47抑制促进免疫逃避.
用HSP47抑制与CD155/TIGIT阻断的联合疗法可以提高治疗效果.
这表明开发新型组合癌症疗法的有前途战略.

关键词:

骨癌骨癌是一种骨癌.免疫检查点抑制剂免疫检查点抑制剂免疫治疗是一种免疫疗法.

更多相关视频

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Receptor Downregulation in MVBs

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...